000444093 001__ 444093
000444093 005__ 20230210182652.0
000444093 0247_ $$2CORDIS$$aG:(EU-Grant)101003627$$d101003627
000444093 0247_ $$2CORDIS$$aG:(EU-Call)H2020-SC1-PHE-CORONAVIRUS-2020$$dH2020-SC1-PHE-CORONAVIRUS-2020
000444093 0247_ $$2originalID$$acorda__h2020::101003627
000444093 035__ $$aG:(EU-Grant)101003627
000444093 150__ $$aSwift COronavirus therapeutics REsponse$$y2020-04-01 - 2022-09-30
000444093 371__ $$aAix-Marseille University$$bAMU$$dFrance$$ehttp://www.univ-amu.fr/$$vCORDIS
000444093 371__ $$aJANSSEN PHARMACEUTICA NV$$dBelgium$$ehttp://www.janssen.com/$$vCORDIS
000444093 371__ $$aUniversity of Lübeck$$bUniversity of Lübeck$$dGermany$$ehttp://www.uni-luebeck.de/$$vCORDIS
000444093 371__ $$aHelmholtz-Zentrum für Infektionsforschung GmbH$$bHelmholtz Centre for Infection Research$$dGermany$$ehttp://www.helmholtz-hzi.de/$$vCORDIS
000444093 371__ $$aFederal Department of Home Affairs$$bFDHA$$dSwitzerland$$ehttp://www.edi.admin.ch/?lang=en$$vCORDIS
000444093 371__ $$aKU Leuven$$bKUL$$dBelgium$$ehttp://www.kuleuven.be/english$$vCORDIS
000444093 371__ $$aACADEMISCH ZIEKENHUIS LEIDEN$$bLeiden University Medical Center$$dNetherlands$$ehttp://www.lumc.nl$$vCORDIS
000444093 371__ $$aUtrecht University$$bUtrecht University$$dNetherlands$$ehttp://www.uu.nl/en$$vCORDIS
000444093 372__ $$aH2020-SC1-PHE-CORONAVIRUS-2020$$s2020-04-01$$t2022-09-30
000444093 450__ $$aSCORE$$wd$$y2020-04-01 - 2022-09-30
000444093 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000444093 680__ $$aCoronavirus 2019-nCoV has become a worldwide public health emergency, and the lack of vaccines and drugs to immediately address this outbreak is painfully clear. Even if the epidemic can be stopped, the virus may return in the same or a modified form. More than vaccines and therapeutic antibodies, antiviral drugs can target highly conserved viral functions and have the broad-spectrum activity that is critical to combat current and future outbreaks. 

Since the 2003 SARS outbreak, as leading academic coronavirus researchers, we have collaborated to understand and inhibit coronavirus replication. We defined viral key functions, developed tools for inhibitor screening, and identified/engineered drug candidates. Until 2015, our collaborative efforts were supported by the FP7 SILVER project, but they have been continued until this very day. As European coronavirus experts, we now propose the SCORE project, supported by a leading pharmaceutical company. Virologists, biochemists, structural biologists, and medicinal chemists will collaborate in a state-of-the-art drug discovery/design program that targets 2019-nCoV. Our vast SARS-CoV-derived expertise and unique toolbox will be a major asset to achieve immediate impact.

We will target the virus using 5 independent approaches: (i) using of (combinations of) FDA-approved drugs, (ii) targeting viral RNA synthesis, (iii) inhibiting coronavirus proteases, (iv) blocking virus entry, (v) discovery and development of new antivirals. This program will be supplemented with 2019-nCoV toolbox and animal model development. We aim to deliver proof-of-concept for selected compounds within 6-9 months, after which they will be offered for further use/development. This will contribute to short-term solutions for the on-going crisis and also pave the way for mid/long-term success in developing inhibitors that will be active against (evolving) 2019-nCoV strains, other SARS-like coronaviruses, and potentially (beta)coronaviruses at large.
000444093 909CO $$ooai:juser.fz-juelich.de:879958$$pauthority$$pauthority:GRANT
000444093 909CO $$ooai:juser.fz-juelich.de:879958
000444093 970__ $$aoai:dnet:corda__h2020::ac79baa81cc704f018c1dd7768537206
000444093 980__ $$aG
000444093 980__ $$aCORDIS
000444093 980__ $$aAUTHORITY